Kenvue (NYSE:KVUE) Given New $19.00 Price Target at Barclays

Kenvue (NYSE:KVUE) had its price objective raised by research analysts at Barclays from $18.00 to $19.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Barclays‘s price target would indicate a potential upside of 5.44% from the company’s current price.

A number of other analysts have also recently commented on the stock. Weiss Ratings reiterated a “hold (c-)” rating on shares of Kenvue in a research note on Friday, January 9th. Citigroup raised their price target on shares of Kenvue from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Wednesday, February 18th. Zacks Research upgraded shares of Kenvue from a “strong sell” rating to a “hold” rating in a research note on Wednesday, November 26th. Jefferies Financial Group downgraded Kenvue from a “buy” rating to a “hold” rating and cut their target price for the company from $23.00 to $18.00 in a research report on Friday, January 30th. Finally, UBS Group raised their target price on Kenvue from $17.00 to $19.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 18th. Three equities research analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $19.58.

Kenvue Stock Down 1.3%

KVUE stock traded down $0.23 on Friday, hitting $18.02. 1,120,162 shares of the company’s stock were exchanged, compared to its average volume of 48,890,094. The firm has a 50 day moving average price of $17.82 and a two-hundred day moving average price of $17.47. Kenvue has a 12-month low of $14.02 and a 12-month high of $25.17. The stock has a market cap of $34.54 billion, a P/E ratio of 23.40, a price-to-earnings-growth ratio of 4.17 and a beta of 0.51. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.96.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Tuesday, February 17th. The company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.05. Kenvue had a return on equity of 19.72% and a net margin of 9.72%.The business had revenue of $3.78 billion during the quarter, compared to the consensus estimate of $3.68 billion. During the same quarter last year, the company earned $0.26 earnings per share. The company’s quarterly revenue was up 3.2% on a year-over-year basis. As a group, equities research analysts expect that Kenvue will post 1.14 EPS for the current fiscal year.

Insider Buying and Selling at Kenvue

In other news, Director Jeffrey C. Smith purchased 3,200,000 shares of the stock in a transaction that occurred on Friday, December 12th. The shares were purchased at an average cost of $17.37 per share, with a total value of $55,584,000.00. Following the completion of the acquisition, the director owned 27,307,632 shares of the company’s stock, valued at approximately $474,333,567.84. This represents a 13.27% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.68% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Kenvue

A number of institutional investors have recently modified their holdings of KVUE. Vanguard Group Inc. raised its holdings in Kenvue by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 234,951,484 shares of the company’s stock worth $4,052,913,000 after purchasing an additional 1,604,040 shares during the period. State Street Corp raised its stake in shares of Kenvue by 3.5% during the 4th quarter. State Street Corp now owns 118,865,134 shares of the company’s stock worth $2,050,424,000 after buying an additional 4,063,257 shares during the period. Geode Capital Management LLC raised its stake in shares of Kenvue by 0.8% during the 4th quarter. Geode Capital Management LLC now owns 49,862,574 shares of the company’s stock worth $856,778,000 after buying an additional 371,322 shares during the period. Independent Franchise Partners LLP lifted its position in shares of Kenvue by 56.3% during the 4th quarter. Independent Franchise Partners LLP now owns 48,146,476 shares of the company’s stock valued at $830,527,000 after buying an additional 17,343,785 shares in the last quarter. Finally, Norges Bank acquired a new stake in Kenvue in the 4th quarter valued at $756,862,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.